ARTICLE | Company News
Aquila other research news
September 11, 2000 7:00 AM UTC
AQLA received a $127,989 Phase I SBIR grant from the National Institute of Allergy and Infectious Diseases to develop vaccines to prevent S. aureus infections using AQLA's CD1 antigen presentation imm...